Interim analysis of a Phase 4 study of ARD (RA 25%, SLE 25%) patients shows recombinant herpes zoster vaccine(RZV) good safety profile, with no impact on disease activity (flare rates: 13.6% vs. 12.4%). Immunogenicity: 93% response in ARDs vs. 99% in controls. Rituximab & MMF… https://t.co/U3s48fLduX https://t.co/WTvD5shtXB

• https://x.com/i/web/status/1857849868129112408
• https://x.com/synovialjoints/status/1857849868129112408/photo/1

Study on socioeconomic factors in SLE hospitalizations - US wide data - No insurance & non-metro areas linked to shorter LOS, lower costs, higher mortality - Higher income & age increase charges - Targeted interventions needed to improve outcomes #ACR24 abst#0615 @RheumNow

Study on pregnancy outcome disparities in SLE: - Analyzed 685 women, 1888 pregnancies - Pre-SLE state linked to fewer live births, higher preeclampsia risk - Outcomes worse post-SLE diagnosis #ACR24 abst#0440 @RheumNow https://t.co/NpEYQZ73uo

• https://x.com/bella_mehta/status/1857851377906757692/photo/1
• https://x.com/bella_mehta/status/1857851377906757692/photo/1

Briefly highlighting this poster, always looking for a non-Georg Schett CAR-T study to see if their results replicate All 10 pts in this one had a "complete humoral response," normalizing antibodies & experiencing long term drug-free remission #ACR24 @RheumNow Abstr#0673 https://t.co/pjOjRnJVhO

• https://x.com/EBRheum/status/1857839298227077451/photo/1

This poster makes me happy for so many reasons 😆 Aggressive & descriptive title? ☑️ Pretty chloropleth map? ☑️ Dunks on hamfisted EMR tools trying to replace patient-physician interactions? ☑️ @RheumNow #ACR24 Abstr#0668 ThereAreNoShortcuts https://t.co/IXYaHAi15q

• https://x.com/EBRheum/status/1857837788168589420/photo/1

This is likely an oversimplification, but I've been looking for exactly this diagram Inhibiting various TYKs/JAKs corresponds to various downstream cytokine inhibition @EricFMorand does it make sense to see this as anifrolumab+ustekinumab? No? @rheumnow #ACR24 Abstr#0662 https://t.co/thti6s5TR3

• https://x.com/EBRheum/status/1857836781628174735/photo/1
• https://x.com/EBRheum/status/1857836781628174735/photo/1

Ok so trivial tweet here but I just love the name of this outcome measure... "LFA-REAL" 😄😆 Serious topic though; PRO's are huge in SLE research! @RheumNow #ACR24 Abstr#0626 https://t.co/w34zTNjSbH

• https://x.com/EBRheum/status/1857834013425311941/photo/1

🧬 #SLE patients show major community mobility limits: 50% don't leave their neighborhood weekly without help. Life Space Assessment finds lower mobility vs. other chronic conditions. Better mobility linked to higher SES & lower disease activity. @RheumNow #ACR24 abst#0145 https://t.co/2sfXNlJ9JD

• https://x.com/bella_mehta/status/1857823695638564985/photo/1

Shu et al. Rituximab followed by Telitacicept in refractory/severe APS. Significantly fewer new clinical events in Telitacicept group over 24 weeks (1/21 vs. 6/20) @RheumNow #ACR24 Abstr#0129 https://t.co/hjUQkNNk5w https://t.co/QLQbZ3wQx0

• The Efficacy and Safety of Telitacicept Following Rituximab Immunotherapy on An…
• https://x.com/RichardPAConway/status/1857822940433363387/photo/1

🔍 Study on lupus & APS highlights key links! APS patients face higher rates of developing SLE, and vice versa. Notable predictors: females, lupus anticoagulant, and specific antibodies. These insights stress the need for vigilant monitoring in both. #ACR24 @RheumNow Abst#0119